NCT01739309 2023-09-21Study of LY2835219 for Mantle Cell LymphomaEli Lilly and CompanyPhase 2 Completed28 enrolled 20 charts
NCT02745769 2019-03-05A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted AgentsEli Lilly and CompanyPhase 1 Completed23 enrolled